The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta
Open accessAbstract
Osteogenesis imperfecta (OI) is a heritable disorder, in both a dominant and recessive manner, of connective tissue characterized by brittle bones, fractures and extraskeletal manifestations. How structural mutations of type I collagen (dominant OI) or of its post-translational modification machinery (recessive OI) can cause abnormal quality and quantity of bone is poorly understood. Notably, the clinical overlap between dominant and recessive forms of OI suggests common molecular pathomechanisms. Here, we show that excessive transforming growth factor-β (TGF-β) signaling is a mechanism of OI in both recessive (Crtap−/−) and dominant (Col1a2tm1.1Mcbr) OI mouse models. In the skeleton, we find higher expression of TGF-β target genes, higher ratio of phosphorylated Smad2 to total Smad2 protein and higher in vivo Smad2 reporter activity. Moreover, the type I collagen of Crtap−/− mice shows reduced binding to the small leucine-rich proteoglycan decorin, a known regulator of TGF-β activity. Anti–TGF-β treatment using the neutralizing antibody 1D11 corrects the bone phenotype in both forms of OI and improves the lung abnormalities in Crtap−/− mice. Hence, altered TGF-β matrix-cell signaling is a primary mechanism in the pathogenesis of OI and could be a promising target for the treatment of OI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome
Neptune, E. R., Frischmeyer, P. A., Arking, D. E., Myers, L., Bunton, T. E., Gayraud, B., Ramirez, F., Sakai, L. Y., & Dietz, H. C. (2003) · Nature Genetics · doi:10.1038/ng1116 · Cited by 1,404
Rauch, F., & Glorieux, F. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16051-0 · Cited by 1,167
TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation
Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., Zhao, L., Nagy, T. R., Peng, X., Hu, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1979 · Cited by 1,165
Hildebrand, A., Romarís, M., Rasmussen, L. M., Heinegård, D., Twardzik, D. R., Border, W. A., & Ruoslahti, E. (1994) · Biochemical Journal · doi:10.1042/bj3020527 · Cited by 994
Marini, J. C., Forlino, A., Cabral, W. A., Barnes, A. M., San Antonio, J. D., Milgrom, S., Hyland, J. C., Körkkö, J., Prockop, D. J., De Paepe, A., et al. (2007) · Human Mutation · doi:10.1002/humu.20429 · Cited by 764
Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., & Rifkin, D. B. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1042 · Cited by 757
Transforming Growth Factor-β1 to the Bone
Janssens, K., ten Dijke, P., Janssens, S., & Van Hul, W. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0001 · Cited by 710
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells
Xian, L., Wu, X., Pang, L., Lou, M., Rosen, C. J., Qiu, T., Crane, J., Frassica, F., Zhang, L., Rodriguez, J. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2793 · Cited by 631
CRTAP Is Required for Prolyl 3- Hydroxylation and Mutations Cause Recessive Osteogenesis Imperfecta
Morello, R., Bertin, T. K., Chen, Y., Hicks, J., Tonachini, L., Monticone, M., Castagnola, P., Rauch, F., Glorieux, F. H., Vranka, J., et al. (2006) · Cell · doi:10.1016/j.cell.2006.08.039 · Cited by 531
Self-citationAlliston, T., Choy, L., Ducy, P., Karsenty, G., & Derynck, R. (2001) · The EMBO Journal · doi:10.1093/emboj/20.9.2254 · Cited by 526
Cited by
Remodelling the extracellular matrix in development and disease
Bonnans, C., Chou, J., & Werb, Z. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3904 · Cited by 4,367
Wu, M., Chen, G., & Li, Y.-P. (2016) · Bone Research · doi:10.1038/boneres.2016.9 · Cited by 1,553
Marini, J. C., Forlino, A., Bächinger, H. P., Bishop, N. J., Byers, P. H., Paepe, A. D., Fassier, F., Fratzl-Zelman, N., Kozloff, K. M., Krakow, D., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.52 · Cited by 842
Self-citationBMP signalling in skeletal development, disease and repair
Salazar, V. S., Gamer, L. W., & Rosen, V. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.12 · Cited by 822
Wu, M., Wu, S., Chen, W., & Li, Y.-P. (2024) · Cell Research · doi:10.1038/s41422-023-00918-9 · Cited by 445
Amirrah, I. N., Lokanathan, Y., Zulkiflee, I., Wee, M. F. M. R., Motta, A., & Fauzi, M. B. (2022) · Biomedicines · doi:10.3390/biomedicines10092307 · Cited by 426
Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins
Robertson, I. B., & Rifkin, D. B. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021907 · Cited by 403
BMP signalling: agony and antagony in the family
Brazil, D. P., Church, R. H., Surae, S., Godson, C., & Martin, F. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.004 · Cited by 306
Dole, N. S., Mazur, C. M., Acevedo, C., Lopez, J. P., Monteiro, D. A., Fowler, T. W., Gludovatz, B., Walsh, F., Regan, J. N., Messina, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.115 · Cited by 173
Molecular insights into prolyl and lysyl hydroxylation of fibrillar collagens in health and disease
Gjaltema, R. A. F., & Bank, R. A. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1269716 · Cited by 175
Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma
Nomura, M., Rainusso, N., Lee, Y.-C., Dawson, B., Coarfa, C., Han, R., Larson, J. L., Shuck, R., Kurenbekova, L., & Yustein, J. T. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz026 · Cited by 99
Self-citationHigh-Dose TGF-β1 Impairs Mesenchymal Stem Cell–Mediated Bone Regeneration via Bmp2 Inhibition
Xu, J., Liu, J., Gan, Y., Dai, K., Zhao, J., Huang, M., Huang, Y., Zhuang, Y., & Zhang, X. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3871 · Cited by 68
The Osteocyte Transcriptome Is Extensively Dysregulated in Mouse Models of Osteogenesis Imperfecta
Zimmerman, S. M., Dimori, M., Heard‐Lipsmeyer, M. E., & Morello, R. (2019) · JBMR Plus · doi:10.1002/jbm4.10171 · Cited by 41
Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta
Jeong, Y., Daghlas, S. A., Xie, Y., Hulbert, M. A., Pfeiffer, F. M., Dallas, M. R., Omosule, C. L., Pearsall, R. S., Dallas, S. L., & Phillips, C. L. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3473 · Cited by 36
Quantitative increase in T regulatory cells enhances bone remodeling in osteogenesis imperfecta
Kang, I.-H., Baliga, U. K., Chatterjee, S., Chakraborty, P., Choi, S., Buchweitz, N., Li, H., Wu, Y., Yao, H., Mehrotra, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104818 · Cited by 28
Sun, B., Wu, H., Lu, J., Zhang, R., Shen, X., Gu, Y., Shi, C., Zhang, Y., & Yuan, W. (2023) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.10.012 · Cited by 28
Efficacy of Platelet-Rich Plasma in the Treatment of Fractures: A Meta-Analysis
Xu, Z., Hu, H., Wu, B., Huang, C., Liu, Q., & Chen, B. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/5105725 · Cited by 8
Retracted
Metadata
- Authors
- Grafe, I., Yang, T., Alexander, S., Homan, E. P., Lietman, C., Jiang, M. M., Bertin, T., Munivez, E., Chen, Y., Dawson, B., Ishikawa, Y., Weis, M. A., Sampath, T. K., Ambrose, C., Eyre, D., Bächinger, H. P., & Lee, B.
- Venue
- Nature Medicine
- Published
- 2014-05-04
- Volume
- 20
- Issue
- 6
- Pages
- 670-675
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2056317902
- Cited by
- 306
- References
- 45
- FWCI
- 17.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.